NeuroMetrix, Inc., (Nasdaq: NURO) today reported that it has signed a collaboration agreement with Biomedix to comarket DPNCheck for peripheral neuropathy detection within Medicare Advantage and other value-based care markets. NeuroMetrix and Biomedix provide complementary diagnostic tests to physicians and health plans. Within these markets, healthcare providers are focused on detecting and documenting chronic health conditions to determine risk and prevent their costly and debilitating complications.
Biomedix will integrate DPNCheck sural nerve conduction data into the Biomedix Xchange population health platform. This will simplify the documentation process for health plans by combining results from multiple diagnostic tests into one data exchange file for the electronic medical record system.
“We are pleased to partner with Biomedix,” said Shai N. Gozani, M.D., Ph.D., President and CEO of NeuroMetrix, Inc. “Having Biomedix comarket DPNCheck will provide valuable exposure within Medicare Advantage and potentially other value-based care organizations. The integration of DPNCheck data into the Biomedix Xchange platform will give customers a streamlined approach to documenting diagnostic results performed during health risk assessments.”
“The NeuroMetrix partnership represents a strategic milestone in our effort to improve the delivery of cost-effective care to patients in clinics as well as in homes,” said John Romans, CEO of Biomedix. “Integrating DPNCheck into our HITRUST-certified platform broadens our ability to identify, treat, and manage conditions such as peripheral neuropathy and peripheral artery disease (PAD); two chronic disease states that are highly prevalent in Medicare populations.”
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Source: BioSpace
